ArticleMolecular therapy. Nucleic acids2019
Drug Resistance-Related Competing Interactions of lncRNA and mRNA across 19 Cancer Types.
Article in Molecular therapy. Nucleic acids, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 36 citations in OpenAlex.
- Long Non-Coding RNAs in HER2-Positive Breast Cancer: From Resistance Mechanisms to Translational Potential.Oncology research · 2026Review
- Long non-coding RNA LINC02499 regulates the expression of CYP3A5 in human liver cells.Archives of toxicology · 2025Article
- A Novel Competing Endogenous RNA Network Reveals Potential Mechanisms and Biomarkers of Chemoresistance in Lung Adenocarcinoma.Journal of Cancer · 2025Article
- Competing endogenous RNAs (ceRNAs) and drug resistance to cancer therapy.Cancer drug resistance (Alhambra, Calif.) · 2024Review
- New long noncoding RNA biomarkers and ceRNA networks on miR-616-3p in colorectal cancer: Bioinformatics-based study.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2024Article
- A ten long noncoding RNA-based prognostic risk model construction and mechanism study in the basal-like immune-suppressed subtype of triple-negative breast cancer.Translational cancer research · 2023Article
- Multi-Omics Mining of lncRNAs with Biological and Clinical Relevance in Cancer.International journal of molecular sciences · 2023Review
- Insight into the regulatory mechanism of dynamic chromatin 3D interactions during cardiomyocyte differentiation in human.Molecular therapy. Nucleic acids · 2023Article
- Soft Tissue Ewing Sarcoma Cell Drug Resistance Revisited: A Systems Biology Approach.International journal of environmental research and public health · 2023Article
- Identification and functional analysis of N6-methyladenine (mCancer medicine · 2023Article
- Article
- LncRNA LINC00511 promotes COL1A1-mediated proliferation and metastasis by sponging miR-126-5p/miR-218-5p in lung adenocarcinoma.BMC pulmonary medicine · 2022Article
- A score of DNA damage repair pathway with the predictive ability for chemotherapy and immunotherapy is strongly associated with immune signaling pathway in pan-cancer.Frontiers in immunology · 2022Article
- Long non-coding RNA NORAD/miR-224-3p/MTDH axis contributes to CDDP resistance of esophageal squamous cell carcinoma by promoting nuclear accumulation of β-catenin.Molecular cancer · 2021Article
- LncRNA as a multifunctional regulator in cancer multi-drug resistance.Molecular biology reports · 2021Review
- Comprehensive characterization of a drug-resistance-related ceRNA network across 15 anti-cancer drug categories.Molecular therapy. Nucleic acids · 2021Article
- LINC00488 stimulates the progression of esophageal cancer by targeting microRNA-485-5p.Oncology letters · 2021Article
- LncRNA APCDD1L-AS1 induces icotinib resistance by inhibition of EGFR autophagic degradation via the miR-1322/miR-1972/miR-324-3p-SIRT5 axis in lung adenocarcinoma.Biomarker research · 2021Article
- Paving the way for small-molecule drug discovery.American journal of translational research · 2021Review
- Omics and Computational Modeling Approaches for the Effective Treatment of Drug-Resistant Cancer Cells.Frontiers in genetics · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug resistance is a common cause of treatment failure in cancer therapy, and molecular mechanisms need further exploration. Competing endogenous RNAs (ceRNAs) can influence drug response by participating in various biological processes, including regulation of cell cycle, signal transduction, and so on. In this study, we systematically explored resistance from the perspective of ceRNA modules. First, we constructed a general ceRNA network, involving 83 long non-coding RNAs (lncRNAs) and 379 mRNAs. Next, we identified the drug resistance-related modules for 138 drugs and 19 cancer types, totaling 758 drug-cancer conditions. Function analysis showed that resistance-related biological processes were enriched in these modules, such as regulation of cell proliferation, DNA damage repair, and so on. Pan-drug and pan-cancer analyses revealed some common and specific modules across multiple drugs or cancers. In addition, we also found that drug pairs with common modules have similar structure, indicating high risk for multidrug resistance (MDR). Finally, we speculated that ceRNA pair GAS5-RPL8 could regulate drug resistance because low expression of GAS5 would enhance microRNA (miRNA)-mediated inhibition of RPL8. In total, we investigated the drug resistance by using ceRNA modules and proposed that ceRNA modules may be new markers for drug resistance that indicated a possible novel mechanism.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.